SEARCH

SEARCH BY CITATION

References

  • 1
    Epstein M. Resistant hypertension: prevalence and evolving concepts. J Clin Hypertens. 2007;9(Suppl 1):26.
  • 2
    Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 3
    Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:14031419.
  • 4
    Brown MJ, Cruickshank JK, Dominiczak AF, et al.; Executive Committee, British Hypertension Society. Better blood pressure control: how to combine drugs. J Hum Hypertens. 2003;17:8186.
  • 5
    Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:24172428.
  • 6
    Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:9951003.
  • 7
    Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. LIFE Study Investigators. Circulation. 2003;108:684690.
  • 8
    Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a β-blocker. Am J Hypertens. 1995;8:229236.
  • 9
    Tjugen TB, Flaa A, Kjeldsen SE. High heart rate as predictor of essential hypertension: the hyperkinetic state, evidence of prediction of hypertension, and hemodynamic transition to full hypertension. Prog Cardiovasc Dis. 2009;52:2025.
  • 10
    Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension. 2005;45:880886.
  • 11
    MacGregor GA, Markandu ND, Smith SJ, et al. Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine. J Cardiovasc Pharmacol. 1985;7(Suppl 1):S82S87.
  • 12
    Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized double-blinded trial. Lancet. 2007;370:221229.
  • 13
    Cappuccio FP, MacGregor GA. Combination therapy in hypertension. In: LaraghJH, BrennerBM, eds. Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed. New York: Raven Press; 1995:29692983.
  • 14
    Sutton JM, Bagby SP. Nontraditional combination pharmacotherapy of hypertension. Cleve Clin J Med. 1992;59:459466.
  • 15
    Setaro JF, Black HR. Refractory hypertension. N Engl J Med. 1992;32:543547.
  • 16
    Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39:982988.
  • 17
    Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension. Results from a randomized trial. Hypertension. 2009;54:475481.
  • 18
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 19
    Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352358.
  • 20
    Khosla N, Chua DY, Elliott WJ, et al. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens. 2005;7:354356.
  • 21
    Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43:49.
  • 22
    Izzo JL, Neutel JM, Silfani I, et al. on behalf of the Study Investigators. Titration of HCTZ to 50 mg daily in individuals with Stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. J Clin Hypertens. 2007;9:4548.
  • 23
    Singer DR, Markandu ND, Sugden AL, et al. Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide. Hypertension. 1991;17:798803.
  • 24
    Vaughan ED, Laragh JH, Gavras I, et al. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol. 1973;32:523532.
  • 25
    Brest AN. Spironolactone in the treatment of hypertension: a review. Clin Ther. 1985;8:568585.
  • 26
    Niarchos AP, Laragh JH. Effects of diuretic therapy in low-, normal- and high-renin isolated systolic systemic hypertension. Am J Cardiol. 1984;53:797801.
  • 27
    Brooks CS, Johnson CA, Kotchen JM, et al. Diuretic therapies in low renin and normal renin essential hypertension. Clin Pharmacol Ther. 1977;22:1420.
  • 28
    Egan BM, Basile JN, Rehman SU, et al. Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22:792801.
  • 29
    Laragh JH. Vasoconstriction–volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med. 1973;55:261274.
  • 30
    Licht JH, Haley RJ, Pugh B, et al. Diuretic regimens in essential hypertension. A comparison of hypokalemic effects, BP control, and cost. Arch Intern Med. 1983;143:16941699.
  • 31
    Broekhuysen J, Deger F, Douchamps J, et al. Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur J Clin Pharmacol. 1986;31(Suppl):2934.
  • 32
    Wollam GL, Tarazi RC, Bravo EL, et al. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med. 1982;72:929938.
  • 33
    Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925930.
  • 34
    Jansen PM, Danser AHJ, Imholz BP, et al. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27:680691.
  • 35
    Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008;2:462468.
  • 36
    Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31:153158.
  • 37
    Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46:481487.
  • 38
    Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892896.
  • 39
    Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens. 1998;16:19791987.
  • 40
    Mann SJ. Neurogenic essential hypertension revisited: the case for increased clinical and research attention. Am J Hypertens. 2003;16:881888.
  • 41
    Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1997;17:719734.
  • 42
    Jorgensen RS, Johnson BT, Kolodziej ME, et al. Elevated blood pressure and personality: a meta-analytic review. Psychol Bull. 1996;120:293320.
  • 43
    Mann SJ, Gerber LM. Psychological characteristics and responses to antihypertensive drug therapy. J Clin Hypertens. 2002;4:2534.
  • 44
    Mann SJ, Gerber LM. Low dose α/β blockade in the treatment of essential hypertension. Am J Hypertens. 2001;14:553558.
  • 45
    Englert RG, Barlage U. The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by β blockers. Am Heart J. 1991;121:311316.
  • 46
    Searle M, Dathan R, Dean S, et al. Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. Eur J Clin Pharmacol. 1990;39:299300.
  • 47
    Pool JL. Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials. Am Heart J. 1991;122:926931.
  • 48
    Holtzman JL, Kaihlanen PM, Rider A, et al. Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. Arch Intern Med. 1988;148:539543.
  • 49
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:19671975.
  • 50
    Julius S. The blood pressure seeking properties of the central nervous system. J Hypertens. 1988;6:177185.
  • 51
    Ulrych M. Changes of general hemodynamics during stressful mental arithmetic and nonstressing quiet conversation and modification of the latter by β-adrenergic blockade. Clin Sci. 1969;36:453461.
  • 52
    Andren L, Hansson L, Eggertsen R, et al. Circulatory effects of noise. Acta Med Scand. 1983;213:3135.
  • 53
    Mills PJ, Dimsdale JE. Cardiovascular reactivity to psychosocial stressors. A review of the effects of β-blockade. Psychosomatics. 1991;32:209220.
  • 54
    Dimsdale JE, Mills P, Ziegler M, et al. Converting enzyme inhibition and blood pressure reactivity to psychological stressors. Hypertension. 1992;20:210213.
  • 55
    Shapiro AP. Pressor responses to noxious stimuli in hypertensive patients. Effects of reserpine and chlorothiazide. Circulation. 1962;26:242250.
  • 56
    Maconochie JG, Richards DA, Woodings EP. Modification of pressor responses induced by ‘cold’. Br J Clin Pharmacol. 1977;4:389P.
  • 57
    Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clinic Pharmacokinet. 1994;26:335346.
  • 58
    McNeil JJ, Anderson AE, Louis WJ, et al. Pharmacokinetics and pharmacodynamic studies of laβlol in hypertensive subjects. Br J Clin Pharmacol. 1979;8(Suppl 2):157S161S.
  • 59
    Rosenthal T, Rabinowitz B, Boichis H, et al. Use of laβlol in hypertensive patients during discontinuation of clonidine therapy. Eur J Clin Pharmacol. 1981;20:237240.
  • 60
    Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press. 2009;18:7477.
  • 61
    Messerli FH, Grossman E. Β-blockers in hypertension: is carvedilol different? Am J Cardiol. 2004;93(suppl):7B12B.
  • 62
    Salvetti A, Arzilli F. Chronic dose-response curve of enalapril in essential hypertensives. An Italian multicenter study. Am J Hypertens. 1989;2:352354.
  • 63
    Canter D, Frank GJ, Knapp LE, et al. Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. J Hum Hypertens. 1994;8:155162.
  • 64
    Skoularigis J, Strugo V, Weinberg J, et al. Effects of amlodipine on 24-hour ambulatory blood pressure profiles, electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension. J Clin Pharmacol. 1995;35:10521059.
  • 65
    Englert RG, Mauersberger H. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy. Am Heart J. 1988;116:18261832.
  • 66
    Mann SJ. The silent epidemic of thiazide-induced hyponatremia. J Clin Hypertens. 2008;10:477484.
  • 67
    Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in β blockers. Am Heart J. 1980;100:160178.
  • 68
    Bengtsson C, Johnsson G, Regardh CG. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther. 1975;17:400408.
  • 69
    Van Peer A, Snoeck E, Woestenborghs R, et al. Clinical pharmacokinetics of nebivolol. A review. Drug Invest. 1991;3(Suppl 1):2530.
  • 70
    Lorimer AR, Smedsrud T, Walker P, et al. Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol. 1988;12(Suppl 7):S89S93.
  • 71
    Kassler-Taub K, Littlejohn T, Elliott W, et al.; for the Irbesaran/Losartan Study Investigators. Comparative efficacy of two angiotensin II receptor anatagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens. 1998;11:445453.
  • 72
    Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5:4150.
  • 73
    Stergiou GS, Efstathiou SP, Roussias LG, et al. Intraindividual blood pressure responses to angiotensin-converting enzyme inhibition and angiotensin receptor blockade. J Clin Hypertens 2005;7:1823.
  • 74
    Brown MJ, Dickerson JE. Α-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. J Hypertens 1995;13:701707.
  • 75
    Murphy MB, Bulpitt CJ, Dollery CT. Role of nifedipine in the treatment of resistant hypertension. Comparison with hydralazine in hospital outpatients. Am J Med. 1984;77:1621.
  • 76
    Kleiner JP, Ball JH, Nelson WP, et al. The outpatient treatment of refractory hypertension with minoxidil. South Med J. 1977;70:814817.
  • 77
    Westwood BE, Wilson M, Heath WC, et al. The unsuitability of minoxidil for the treatment of moderate hypertension. Med J Aust. 1986;145:151152.
  • 78
    Weber MA, Black HR, Bakris GL, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment- resistant hypertension: a randomized double-blind placebo-controlled trial. Lancet. 2009;374:14231431.
  • 79
    Hermida RC, Ayala DE, Fernandez JR, et al. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension. 2009;51:6976.
  • 80
    Wustmann K, Kucera JP, Scheffers I. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension. 2009;54:530536.
  • 81
    Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:12751281.